3024 COMET post hoc analysis: efficacy of long-term avalglucosidase alfa in subgroups of patients with late-onset Pompe disease

Similar Items

• Applying the win ratio method in clinical trials of orphan drugs: an analysis of data from the COMET trial of avalglucosidase alfa in patients with late-onset Pompe disease
  by: Matthias Boentert, et al.
  Published: (2024-01-01)
• Efficacy of Switching Therapy From Alglucosidase Alfa to Avalglucosidase Alfa on Respiratory Function in Participants With Late‐Onset Pompe Disease: A Post Hoc Analysis From the COMET Trial
  by: Priya S. Kishnani, et al.
  Published: (2025-09-01)
• Real-world outcomes from a series of patients with late onset Pompe disease who switched from alglucosidase alfa to avalglucosidase alfa
  by: Chris Carter, et al.
  Published: (2024-01-01)
• Higher dose alglucosidase alfa is associated with improved overall survival in infantile-onset Pompe disease (IOPD): data from the Pompe Registry
  by: Priya S. Kishnani, et al.
  Published: (2023-12-01)
• Efficacy of avalglucosidase alfa on forced vital capacity percent predicted in treatment-naïve patients with late-onset Pompe disease: A pooled analysis of clinical trials
  by: Tahseen Mozaffar, et al.
  Published: (2024-09-01)